B-cell Acute Lymphoblastic Leukemia is an aggressive (fast-growing) type of leukemia (blood cancer) in which too many B-cell lymphoblasts (immature white blood cells) are found in the bone marrow and blood. It is the most common type of acute lymphoblastic leukemia (ALL). Also called B-cell acute lymphocytic leukemia and precursor B-lymphoblastic leukemia.
United States, Texas
MD Anderson Cancer Center, Houston, Texas, United States, 77030
United States, New York
Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10021
Weill Medical College of Cornell University, New York, New York, United States, 10065
United States, Illinois
University of Chicago, Chicago, Illinois, United States, 60647
United States, California
University of California, Los Angeles (UCLA) - Medical Center, Los Angeles, California, United States, 90095
United States, Massachusetts
Dana Farber Cancer Institute, Boston, Massachusetts, United States, 02215
France, Paris
CHU de Nantes - Hôtel-Dieu, Nantes, France, 44093
Hôpital Saint Louis, Unité d'Hématologie Adolescents et Jeunes Adultes Département d'HématologieRecruitingParis, France, 75010
Hôpital Robert Debré - Service d'hémato-immunologieRecruitingParis, France, 75019
Hôpital Lyon Sud, Pierre-Benite, France, 69310
CHU Rennes - Hopital Pontchaillou, Rennes, France, 35033
United States, Pennsylvania
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, 19104
B-cell Acute Lymphoblastic Leukemia Disease InformationAcute Lymphoblastic Leukemia FrequencyWhat is UCART22?Straightforward Generation of Ultrapure Off-the-Shelf Allogeneic CAR-T CellsPre-Clinical Activity of Allogeneic Anti-CD22 CAR-T Cells for the Treatment of B-Cell Acute Lymphoblastic LeukemiaThe Role of Gene Editing Within CAR T-Cell Therapy Development - Interview with Professor Waseem Qasim
Status: Active recruiting
Description
This is a Phase I, first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety, tolerance, clinical activity of UCART22 and to determine the Maximum Tolerated Dose (MTD).
UCART is Universal CAR-T cells. That is T Cells that have been taken from healthy donors (not from patients themselves). TALENS are used to disable the TCRαβ gene T cells use to recognize ’self’ to prevent them from attacking the host (graft vs host).
Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor.
Experimental: Dose Escalation
Part 1: Dose Escalation One administration of UCART22 in the dose escalation phase will explore 4 doses of UCART22 and continue until the Maximum Tolerated Dose (MTD) is identified.
Part 2: Dose Expansion One administration of UCART22 at the MTD.
Last updated: Jun. 26, 2023